

## Xylem Product Security Advisory

### Cybersecurity and Infrastructure Security Agency (CISA)

#### Emergency Directive for VMware Vulnerabilities

May 24, 2022

#### Overview

CISA has issued [Emergency Directive \(ED\) 22-03](#) and released a [Cybersecurity Advisory \(CSA\)](#) in response to active and expected exploitation of multiple vulnerabilities in the following VMware products: VMware Workspace ONE Access (Access), VMware Identity Manager (vIDM), VMware vRealize Automation (vRA), VMware Cloud Foundation, and vRealize Suite Lifecycle Manager.

#### Affected Products

At this time, no affected Xylem products have been identified. This information will be updated as necessary.

#### Security Recommendations

In alignment with CISA, Xylem strongly encourages the following:

- Deploy updates provided in [VMware Security Advisory VMSA-2022-0014](#) or remove the affected instances from networks.
- Organizations with affected VMware products that are accessible from the internet should assume compromise and initiate threat hunting activities using the detection methods provided in the CSA.
- If potential compromise is detected, administrators should apply the incident response recommendations included in the CSA.

#### References

- [CISA: Emergency Directive \(ED\) 22-03](#)
- [CISA: Cybersecurity Advisory \(CSA\)](#)
- [VMware: Security Advisory VMSA-2022-0014](#)
- [Xylem Security Advisories](#)

## Contact Information

For any questions related to this Xylem Security Advisory or to report a security concern, please contact [product.security@xylem.com](mailto:product.security@xylem.com).

## Disclaimer

This document is provided on an as-is basis and does not imply any kind of guarantee or warranty, including the warranties of merchantability or fitness for a particular use. Use of the information in the document or materials linked from the document is at your own risk. Xylem reserves the right to change or update this document any time.

Revision History	
Version	Updates
1.0	Initial draft